Objective:

To evaluate evidence supporting ultraweak photon emission (UPE) as a potential noninvasive biomarker of neural oxidative metabolism and neurological disease.

Background:

UPE, generated by reactive oxygen species during cellular metabolism, has been detected in neural tissue and the human brain. Accumulating data suggest that UPE reflects mitochondrial and redox dynamics—key processes disrupted in neurological disorders such as stroke, epilepsy, and neurodegeneration. Despite these associations, the clinical potential of UPE as a biomarker remains largely unexplored in neurology.

Design/Methods:

A targeted literature review of PubMed and Scopus was conducted to identify experimental and translational studies examining UPE in neurological contexts. Studies were analyzed for emission characteristics, disease specific alterations, and biochemical mechanisms.

Results:

Across studies, UPE intensity increases with glutamatergic stimulation and oxidative stress and is modulated by neurotransmitters. In ischemic stroke models, UPE rises during reperfusion but declines after infarction despite structural recovery, indicating persistent metabolic impairment. In neurodegenerative models, baseline UPE is reduced, and glutamate-evoked responses show diminished amplitude and spectral blue shift, consistent with impaired mitochondrial and synaptic activity. Pharmacologic agents such as donepezil restore UPE profiles toward baseline. In tumor models, malignant cells exhibit distinct spectral signatures compared to normal tissue. Human studies demonstrate correlations between transcranial UPE and EEG activity, suggesting functional coupling with neural metabolism.

Conclusions:

Emerging evidence supports UPE as a sensitive, noninvasive optical marker of neural oxidative metabolism. Its responsiveness to disease state and pharmacologic modulation warrants further translational studies to establish diagnostic thresholds and explore integration with EEG, fMRI, and metabolic imaging in clinical neurology.